| Year |
Citation |
Score |
| 2024 |
Kloske CM, Mahinrad S, Barnum CJ, Batista AF, Bradshaw EM, Butts B, Carrillo MC, Chakrabarty P, Chen X, Craft S, Da Mesquita S, Dabin LC, Devanand D, Duran-Laforet V, Elyaman W, ... ... Harms AS, et al. Advancements in Immunity and Dementia Research: Highlights from the 2023 AAIC Advancements: Immunity Conference. Alzheimer's & Dementia : the Journal of the Alzheimer's Association. PMID 39692624 DOI: 10.1002/alz.14291 |
0.76 |
|
| 2024 |
Samant RR, Standaert DG, Harms AS. The emerging role of disease-associated microglia in Parkinson's disease. Frontiers in Cellular Neuroscience. 18: 1476461. PMID 39564189 DOI: 10.3389/fncel.2024.1476461 |
0.603 |
|
| 2024 |
Corbin-Stein NJ, Childers GM, Webster JM, Zane A, Yang YT, Mudium N, Gupta R, Manfredsson FP, Kordower JH, Harms AS. IFNγ drives neuroinflammation, demyelination, and neurodegeneration in a mouse model of multiple system atrophy. Acta Neuropathologica Communications. 12: 11. PMID 38238869 DOI: 10.1186/s40478-023-01710-x |
0.455 |
|
| 2023 |
Chu Y, Hirst WD, Federoff HJ, Harms AS, Stoessl AJ, Kordower JH. Nigrostriatal tau pathology in parkinsonism and Parkinson's disease. Brain : a Journal of Neurology. PMID 38006313 DOI: 10.1093/brain/awad388 |
0.342 |
|
| 2023 |
Harms AS, Yang YT, Tansey MG. Central and peripheral innate and adaptive immunity in Parkinson's disease. Science Translational Medicine. 15: eadk3225. PMID 37939158 DOI: 10.1126/scitranslmed.adk3225 |
0.674 |
|
| 2023 |
Tansey MG, Harms AS. Editorial: Glial-targeted therapeutics for CNS disease: getting there from here. Frontiers in Cellular Neuroscience. 17: 1231648. PMID 37465212 DOI: 10.3389/fncel.2023.1231648 |
0.552 |
|
| 2023 |
Standaert DG, Harms AS, Childers GM, Webster JM. Disease mechanisms as subtypes: Inflammation in Parkinson disease and related disorders. Handbook of Clinical Neurology. 193: 95-106. PMID 36803825 DOI: 10.1016/B978-0-323-85555-6.00011-4 |
0.659 |
|
| 2022 |
Bloem BR, Brundin P, Harms A, Lindestam Arlehamn C, Tan EK, Williams-Gray CH. Linking Immune Activation and Parkinson's Disease. Journal of Parkinson's Disease. 12: S1-S3. PMID 36155531 DOI: 10.3233/JPD-229005 |
0.33 |
|
| 2022 |
Xu E, Boddu R, Abdelmotilib HA, Sokratian A, Kelly K, Liu Z, Bryant N, Chandra S, Carlisle SM, Lefkowitz EJ, Harms AS, Benveniste EN, Yacoubian TA, Volpicelli-Daley LA, Standaert DG, et al. Pathological α-synuclein recruits LRRK2 expressing pro-inflammatory monocytes to the brain. Molecular Neurodegeneration. 17: 7. PMID 35012605 DOI: 10.1186/s13024-021-00509-5 |
0.814 |
|
| 2021 |
Chellappan R, Guha A, Si Y, Kwan T, Nabors LB, Filippova N, Yang X, Myneni AS, Meesala S, Harms AS, King PH. SRI-42127, a novel small molecule inhibitor of the RNA regulator HuR, potently attenuates glial activation in a model of lipopolysaccharide-induced neuroinflammation. Glia. PMID 34533864 DOI: 10.1002/glia.24094 |
0.321 |
|
| 2021 |
Carlisle SM, Qin H, Hendrickson RC, Muwanguzi JE, Lefkowitz EJ, Kennedy RE, Yan Z, Yacoubian TA, Benveniste EN, West AB, Harms AS, Standaert DG. Sex-based differences in the activation of peripheral blood monocytes in early Parkinson disease. Npj Parkinson's Disease. 7: 36. PMID 33850148 DOI: 10.1038/s41531-021-00180-z |
0.772 |
|
| 2021 |
Williams GP, Schonhoff AM, Jurkuvenaite A, Gallups NJ, Standaert DG, Harms AS. CD4 T cells mediate brain inflammation and neurodegeneration in a mouse model of Parkinson disease. Brain : a Journal of Neurology. PMID 33704423 DOI: 10.1093/brain/awab103 |
0.807 |
|
| 2021 |
Harms AS, Ferreira SA, Romero-Ramos M. Periphery and brain, innate and adaptive immunity in Parkinson's disease. Acta Neuropathologica. PMID 33555429 DOI: 10.1007/s00401-021-02268-5 |
0.492 |
|
| 2020 |
Sulzer D, Antonini A, Leta V, Nordvig A, Smeyne RJ, Goldman JE, Al-Dalahmah O, Zecca L, Sette A, Bubacco L, Meucci O, Moro E, Harms AS, Xu Y, Fahn S, et al. COVID-19 and possible links with Parkinson's disease and parkinsonism: from bench to bedside. Npj Parkinson's Disease. 6: 18. PMID 33574316 DOI: 10.1038/s41531-020-00123-0 |
0.335 |
|
| 2020 |
Harms AS, Kordower JH, Sette A, Lindestam Arlehamn CS, Sulzer D, Mach RH. Inflammation in Experimental Models of α-Synucleinopathies. Movement Disorders : Official Journal of the Movement Disorder Society. PMID 33009855 DOI: 10.1002/mds.28264 |
0.369 |
|
| 2020 |
Sulzer D, Antonini A, Leta V, Nordvig A, Smeyne RJ, Goldman JE, Al-Dalahmah O, Zecca L, Sette A, Bubacco L, Meucci O, Moro E, Harms AS, Xu Y, Fahn S, et al. COVID-19 and possible links with Parkinson's disease and parkinsonism: from bench to bedside. Npj Parkinson's Disease. 6: 18. PMID 32885037 DOI: 10.1038/S41531-020-00123-0 |
0.335 |
|
| 2020 |
Schonhoff AM, Williams GP, Wallen ZD, Standaert DG, Harms AS. Innate and adaptive immune responses in Parkinson's disease. Progress in Brain Research. 252: 169-216. PMID 32247364 DOI: 10.1016/bs.pbr.2019.10.006 |
0.816 |
|
| 2020 |
Williams GP, Marmion DJ, Schonhoff AM, Jurkuvenaite A, Won WJ, Standaert DG, Kordower JH, Harms AS. T cell infiltration in both human multiple system atrophy and a novel mouse model of the disease. Acta Neuropathologica. PMID 31993745 DOI: 10.1007/S00401-020-02126-W |
0.798 |
|
| 2018 |
Schonhoff AM, Harms AS. Glial GLP1R: A novel neuroprotector? Movement Disorders : Official Journal of the Movement Disorder Society. PMID 30427545 DOI: 10.1002/mds.27547 |
0.752 |
|
| 2018 |
Williams GP, Schonhoff AM, Jurkuvenaite A, Thome AD, Standaert DG, Harms AS. Targeting of the class II transactivator attenuates inflammation and neurodegeneration in an alpha-synuclein model of Parkinson's disease. Journal of Neuroinflammation. 15: 244. PMID 30165873 DOI: 10.1186/S12974-018-1286-2 |
0.807 |
|
| 2017 |
Harms AS, Delic V, Thome AD, Bryant N, Liu Z, Chandra S, Jurkuvenaite A, West AB. α-Synuclein fibrils recruit peripheral immune cells in the rat brain prior to neurodegeneration. Acta Neuropathologica Communications. 5: 85. PMID 29162163 DOI: 10.1186/S40478-017-0494-9 |
0.754 |
|
| 2017 |
Harms AS, Thome AD, Yan Z, Schonhoff AM, Williams GP, Li X, Liu Y, Qin H, Benveniste EN, Standaert DG. Peripheral monocyte entry is required for alpha-Synuclein induced inflammation and Neurodegeneration in a model of Parkinson disease. Experimental Neurology. PMID 29155051 DOI: 10.1016/j.expneurol.2017.11.010 |
0.816 |
|
| 2016 |
Qin H, Buckley JA, Li X, Liu Y, Fox TH, Meares GP, Yu H, Yan Z, Harms AS, Li Y, Standaert DG, Benveniste EN. Inhibition of the JAK/STAT Pathway Protects Against α-Synuclein-Induced Neuroinflammation and Dopaminergic Neurodegeneration. The Journal of Neuroscience : the Official Journal of the Society For Neuroscience. 36: 5144-59. PMID 27147665 DOI: 10.1523/Jneurosci.4658-15.2016 |
0.705 |
|
| 2016 |
Volpicelli-Daley LA, Kirik D, Stoyka LE, Standaert DG, Harms AS. How can rAAV-α-synuclein and the fibril α-synuclein models advance our understanding of Parkinson disease? Journal of Neurochemistry. PMID 27018978 DOI: 10.1111/Jnc.13627 |
0.797 |
|
| 2016 |
Thome AD, Harms AS, Volpicelli-Daley LA, Standaert DG. microRNA-155 Regulates Alpha-Synuclein-Induced Inflammatory Responses in Models of Parkinson Disease. The Journal of Neuroscience : the Official Journal of the Society For Neuroscience. 36: 2383-90. PMID 26911687 DOI: 10.1523/Jneurosci.3900-15.2016 |
0.757 |
|
| 2016 |
Ponnazhagan R, Harms AS, Thome AD, Jurkuvenaite A, Gogliotti R, Niswender CM, Conn PJ, Standaert DG. The Metabotropic Glutamate Receptor 4 Positive Allosteric Modulator ADX88178 Inhibits Inflammatory Responses in Primary Microglia. Journal of Neuroimmune Pharmacology : the Official Journal of the Society On Neuroimmune Pharmacology. PMID 26872456 DOI: 10.1007/S11481-016-9655-Z |
0.781 |
|
| 2015 |
Thome AD, Standaert DG, Harms AS. Fractalkine Signaling Regulates the Inflammatory Response in an α-Synuclein Model of Parkinson Disease. Plos One. 10: e0140566. PMID 26469270 DOI: 10.1371/journal.pone.0140566 |
0.808 |
|
| 2015 |
Benveniste E, Qin H, Harms A, Standaert D. ID: 163 Cytokine. 76: 64. DOI: 10.1016/J.Cyto.2015.08.038 |
0.718 |
|
| 2014 |
Lewis TB, Glasgow JN, Harms AS, Standaert DG, Curiel DT. Fiber-modified adenovirus for central nervous system Parkinson's disease gene therapy. Viruses. 6: 3293-310. PMID 25196484 DOI: 10.3390/V6083293 |
0.718 |
|
| 2014 |
Harms AS, Standaert DG. Monocytes and Parkinson's disease: invaders from outside? Movement Disorders : Official Journal of the Movement Disorder Society. 29: 1242. PMID 25124371 DOI: 10.1002/mds.25993 |
0.571 |
|
| 2013 |
Harms AS, Tansey MG. Isolation of murine postnatal brain microglia for phenotypic characterization using magnetic cell separation technology. Methods in Molecular Biology (Clifton, N.J.). 1041: 33-9. PMID 23813367 DOI: 10.1007/978-1-62703-520-0_5 |
0.519 |
|
| 2013 |
Harms AS, Cao S, Rowse AL, Thome AD, Li X, Mangieri LR, Cron RQ, Shacka JJ, Raman C, Standaert DG. MHCII is required for α-synuclein-induced activation of microglia, CD4 T cell proliferation, and dopaminergic neurodegeneration. The Journal of Neuroscience : the Official Journal of the Society For Neuroscience. 33: 9592-600. PMID 23739956 DOI: 10.1523/Jneurosci.5610-12.2013 |
0.83 |
|
| 2012 |
Cao S, Standaert DG, Harms AS. The gamma chain subunit of Fc receptors is required for alpha-synuclein-induced pro-inflammatory signaling in microglia. Journal of Neuroinflammation. 9: 259. PMID 23186369 DOI: 10.1186/1742-2094-9-259 |
0.719 |
|
| 2012 |
Harms AS, Lee JK, Nguyen TA, Chang J, Ruhn KM, Treviño I, Tansey MG. Regulation of microglia effector functions by tumor necrosis factor signaling. Glia. 60: 189-202. PMID 21989628 DOI: 10.1002/Glia.21254 |
0.728 |
|
| 2011 |
Harms AS, Barnum CJ, Ruhn KA, Varghese S, Treviño I, Blesch A, Tansey MG. Delayed dominant-negative TNF gene therapy halts progressive loss of nigral dopaminergic neurons in a rat model of Parkinson's disease. Molecular Therapy : the Journal of the American Society of Gene Therapy. 19: 46-52. PMID 20959812 DOI: 10.1038/Mt.2010.217 |
0.817 |
|
| 2009 |
McAlpine FE, Lee JK, Harms AS, Ruhn KA, Blurton-Jones M, Hong J, Das P, Golde TE, LaFerla FM, Oddo S, Blesch A, Tansey MG. Inhibition of soluble TNF signaling in a mouse model of Alzheimer's disease prevents pre-plaque amyloid-associated neuropathology. Neurobiology of Disease. 34: 163-77. PMID 19320056 DOI: 10.1016/J.Nbd.2009.01.006 |
0.769 |
|
| 2009 |
Harms A, Varghese S, Ruhn K, Trevino I, Blesch A, Tansey M. P3.050 Role of tumor necrosis factor in the progressive phase of dopaminergic neuron death in a rat model of Parkinson's disease Parkinsonism & Related Disorders. 15: S161. DOI: 10.1016/S1353-8020(09)70614-5 |
0.573 |
|
| 2008 |
Lee JK, McCoy MK, Harms AS, Ruhn KA, Gold SJ, Tansey MG. Regulator of G-protein signaling 10 promotes dopaminergic neuron survival via regulation of the microglial inflammatory response. The Journal of Neuroscience : the Official Journal of the Society For Neuroscience. 28: 8517-28. PMID 18716210 DOI: 10.1523/Jneurosci.1806-08.2008 |
0.818 |
|
| Show low-probability matches. |